STERIS (STE) Resumen de Acciones
STERIS plc ofrece productos y servicios de prevención de infecciones en Estados Unidos, Irlanda y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 6/6 |
| Dividendos | 4/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en STE a partir de nuestros controles de riesgos.
STE Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de STERIS plc
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$205.04 |
| Máximo en las últimas 52 semanas | US$269.44 |
| Mínimo de 52 semanas | US$195.14 |
| Beta | 0.91 |
| Cambio en 1 mes | -13.82% |
| Variación en 3 meses | 0.90% |
| Cambio de 1 año | -17.89% |
| Variación en 3 años | -9.17% |
| Variación en 5 años | -4.64% |
| Variación desde la OPV | 9,841.33% |
Noticias y actualizaciones recientes
Recent updates
Actualización de narrativa • Aug 09
STE: North Carolina Expansion And Dividend Growth Will Support Future Upside
Analysts have modestly raised their price target for STERIS to about $262 per share. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E.Seeking Alpha • Jul 27
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking AlphaActualización de narrativa • Jun 24
STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside
Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.Actualización de narrativa • Jun 04
STE: Share Repurchases And Earnings Outlook Will Support Future Upside
Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.Actualización de narrativa • May 11
STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside
Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.Actualización de narrativa • Apr 26
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).Actualización de narrativa • Apr 11
STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.Actualización de narrativa • Mar 28
STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Artículo de análisis • Mar 24
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...Actualización de narrativa • Mar 11
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.Actualización de narrativa • Feb 25
STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.Actualización de narrativa • Feb 10
STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.Actualización de narrativa • Jan 27
STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).Actualización de narrativa • Jan 10
STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.Artículo de análisis • Jan 09
Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Dec 26
Earnings Tell The Story For STERIS plc (NYSE:STE)
With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...Actualización de narrativa • Dec 23
STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).Actualización de narrativa • Dec 09
STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).Actualización de narrativa • Nov 25
STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.Actualización de narrativa • Nov 07
STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.Artículo de análisis • Oct 27
Is STERIS (NYSE:STE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Actualización de narrativa • Sep 05
Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.Seeking Alpha • Mar 22
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking AlphaRentabilidad de los accionistas
| STE | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -4.0% | 0.4% | -0.1% |
| 1Y | -17.9% | -16.3% | 11.9% |
Rentabilidad vs. Industria: Los resultados de STE fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -16.3% el año pasado.
Rentabilidad vs. Mercado: STE obtuvo unos resultados inferiores a los del mercado US, que fueron del 11.9% el año pasado.
Volatilidad de los precios
| STE volatility | |
|---|---|
| STE Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: STE no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de STE (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1985 | 17,937 | Dan Carestio | www.steris.com |
STERIS plc ofrece productos y servicios de prevención de infecciones en Estados Unidos, Irlanda y a escala internacional. Opera a través de tres segmentos: Sanidad, Tecnologías de Esterilización Aplicadas y Ciencias de la Vida. La empresa ofrece productos químicos de limpieza y garantía de esterilidad, sistemas automatizados de reprocesamiento de endoscopios y productos de seguimiento, accesorios de endoscopia, instrumentos, lavadoras y esterilizadores y otras piezas de bienes de equipo, así como equipos utilizados directamente en las salas de procedimientos, incluidas mesas quirúrgicas, luces, servicios de gestión de equipos y soluciones de conectividad; y diversos programas de mantenimiento preventivo, servicios de reparación, consultoría de mejora de procesos personalizados y procesamiento estéril de instrumentos subcontratados, así como servicios de reparación y mantenimiento de instrumentos, dispositivos y endoscopios.
Resumen de fundamentos de STERIS plc
| Estadísticas fundamentales de STE | |
|---|---|
| Capitalización bursátil | US$19.99b |
| Beneficios(TTM) | US$805.00m |
| Ingresos (TTM) | US$6.04b |
24.8x
Ratio precio-beneficio (PE)3.3x
Ratio precio-ventas (PS)¿Está STE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de STE | |
|---|---|
| Ingresos | US$6.04b |
| Coste de los ingresos | US$3.36b |
| Beneficio bruto | US$2.68b |
| Otros gastos | US$1.88b |
| Beneficios | US$805.00m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 8.26 |
| Margen bruto | 44.42% |
| Margen de beneficio neto | 13.33% |
| Ratio deuda/patrimonio | 26.2% |
¿Cómo se ha desempeñado STE a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.3%
Rentabilidad actual por dividendo31%
Ratio de pagos¿Paga STE dividendos fiables?
Ver historial de dividendos e índices de referencia de STE| fechas de dividendos de STERIS | |
|---|---|
| Fecha ex dividendo | Sep 04 2026 |
| Fecha de pago de dividendos | Sep 25 2026 |
| Días hasta ex dividendo | 18 days |
| Días hasta la fecha de pago de dividendos | 3 days |
¿Paga STE dividendos fiables?
Ver historial de dividendos e índices de referencia de STEAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/21 19:14 |
| Precio de las acciones al final del día | 2026/09/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
STERIS plc está cubierta por 17 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |